Kuo Eric J, Wu James X, Li Ning, Zanocco Kyle A, Yeh Michael W, Livhits Masha J
Endocr Pract. 2017 Oct;23(10):1262-1269. doi: 10.4158/EP171933.OR. Epub 2017 Aug 17.
There has been increasing interest in active surveillance of papillary thyroid microcarcinoma. The objective of this study was to characterize the incidence and outcomes of nonoperatively managed differentiated thyroid cancers (DTCs) in California.
Biopsy-proven DTCs from the California Cancer Registry were linked to data from the California Office of Statewide Health Planning and Development (2004-2012). Low-risk tumors were defined as localized disease measuring <4 cm without extrathyroidal extension, nodal involvement, or distant metastasis.
Of 29,978 patients with DTC, 318 (1.1%) were managed nonoperatively. Compared to operatively managed patients, patients managed nonoperatively were older with more comorbidities, larger tumors (mean size, 2.9 cm vs. 2.0 cm), and an increased rate of distant metastasis (20.4% vs. 3.4%). Independent predictors of nonoperative management included increasing age, larger tumor size, papillary histology, and distant metastases. Of 10,795 patients with low-risk tumors, 161 (1.5%) were managed nonoperatively, with tumor size as follows: <1 cm (15.5%), 1 to 2 cm (50.3%), >2 to 3 cm (24.3%), and >3 to 4 cm (9.9%). There were no disease-specific deaths in the low-risk, nonoperative group (median follow-up [interquar-tile range], 21.3 [5.7 to 51.1] months). The proportion of patients managed nonoperatively remained relatively stable over the study period (mean increase 0.1% per year, P = .09). All P values were <.05 unless otherwise stated.
The vast majority of patients with DTCs are treated surgically, suggesting active surveillance is rarely practiced in California. Although follow-up was limited, no disease-specific mortality in nonoperatively managed, low-risk DTCs was observed.
CCI = Charlson Comorbidity Index; CCR = California Cancer Registry; CI = confidence interval; DTC = differentiated thyroid cancer; FTC = follicular thyroid carcinoma; HCC = Hürthle cell carcinoma; IQR = interquartile range; mPTC = papillary thyroid micro-carcinoma; OR = odds ratio; OSPHD = Office of Statewide Health Planning and Development; PTC = papillary thyroid carcinoma.
对甲状腺微小乳头状癌进行主动监测的关注度日益增加。本研究的目的是描述加利福尼亚州非手术治疗的分化型甲状腺癌(DTC)的发病率及转归。
将加利福尼亚癌症登记处活检证实的DTC与加利福尼亚州卫生规划与发展办公室的数据(2004 - 2012年)相关联。低风险肿瘤定义为直径<4 cm的局限性疾病,无甲状腺外侵犯、淋巴结受累或远处转移。
在29,978例DTC患者中,318例(1.1%)接受了非手术治疗。与接受手术治疗的患者相比,接受非手术治疗的患者年龄更大,合并症更多,肿瘤更大(平均大小,2.9 cm对2.0 cm),远处转移率更高(20.4%对3.4%)。非手术治疗的独立预测因素包括年龄增加、肿瘤尺寸增大、乳头状组织学类型和远处转移。在10,795例低风险肿瘤患者中,161例(1.5%)接受了非手术治疗,肿瘤大小分布如下:<1 cm(15.5%),1至2 cm(50.3%),>2至3 cm(24.3%),>3至4 cm(9.9%)。低风险非手术治疗组无疾病特异性死亡(中位随访时间[四分位间距],21.3[5.7至51.1]个月)。在研究期间,非手术治疗患者的比例保持相对稳定(平均每年增加0.1%,P = 0.09)。除非另有说明,所有P值均<0.05。
绝大多数DTC患者接受手术治疗,这表明在加利福尼亚州很少采用主动监测。尽管随访有限,但未观察到非手术治疗的低风险DTC患者有疾病特异性死亡。
CCI = 查尔森合并症指数;CCR = 加利福尼亚癌症登记处;CI = 置信区间;DTC = 分化型甲状腺癌;FTC = 滤泡状甲状腺癌;HCC = 许特尔细胞癌;IQR = 四分位间距;mPTC = 甲状腺微小乳头状癌;OR = 比值比;OSPHD = 州卫生规划与发展办公室;PTC = 乳头状甲状腺癌